Ghent University Academic Bibliography

Advanced

Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification

August Verbruggen UGent, RUTH WITTOEK UGent, BERT VANDER CRUYSSEN UGent and Dirk Elewaut UGent (2012) ANNALS OF THE RHEUMATIC DISEASES. 71(6). p.891-898
abstract
Background Adalimumab blocks the action of tumor necrosis factor-alpha and reduces disease progression in rheumatoid arthritis and psoriatic arthritis. The effects of adalimumab in controlling progression of structural damage in erosive hand osteoarthritis (HOA) were assessed. Methods Sixty patients with erosive HOA on radiology received 40 mg adalimumab or placebo subcutaneously every two weeks during a 12-month randomized double-blind trial. Response was defined as the reduction in progression of structural damage according to the categorical anatomic phase scoring system. Furthermore, subchondral bone, bone plate erosion, and joint-space narrowing were scored according to the continuous Ghent University Score System (GUSS (TM)). Results The disease appeared to be active since 40.0% and 26,7% of patients out of the placebo and adalimumab group, respectively, showed at least one new interphalangeal (IP) joint that became erosive during the 12 months follow-up. These differences were not significant and the overall results showed no effect of adalimumab. Risk factors for progression were then identified and the presence of palpable soft tissue swelling at baseline was recognized as the strongest predictor for erosive progression. In this subpopulation at risk, statistically significant less erosive evolution on the radiological image (3.7%) was seen in the adalimumab treated group compared to the placebo group (14.5%) (P = 0.009). GUSSTM scoring confirmed a less rapid rate of mean increase in the erosion scores during the first 6 months of treatment in patients in adalimumab-treated patients. Conclusion Palpable soft tissue swelling in IP joints in patients with erosive HOA is a strong predictor for erosive progression. In these joints adalimumab significantly halted the progression of joint damage compared to placebo.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
KAPPA-B LIGAND, RHEUMATOID-ARTHRITIS, SYMPTOMATIC HAND OSTEOARTHRITIS, FACTOR-ALPHA, RADIOGRAPHIC OSTEOARTHRITIS, GENERAL-POPULATION, RECEPTOR ACTIVATOR, PREVALENCE, PROGRESSION, DISABILITY
journal title
ANNALS OF THE RHEUMATIC DISEASES
Ann. Rheum. Dis.
volume
71
issue
6
pages
891 - 898
Web of Science type
Article
Web of Science id
000303756400019
JCR category
RHEUMATOLOGY
JCR impact factor
9.111 (2012)
JCR rank
2/29 (2012)
JCR quartile
1 (2012)
ISSN
0003-4967
DOI
10.1136/ard.2011.149849
language
English
UGent publication?
yes
classification
A1
copyright statement
I have retained and own the full copyright for this publication
id
3001265
handle
http://hdl.handle.net/1854/LU-3001265
date created
2012-09-28 15:40:30
date last changed
2012-10-02 12:07:21
@article{3001265,
  abstract     = {Background Adalimumab blocks the action of tumor necrosis factor-alpha and reduces disease progression in rheumatoid arthritis and psoriatic arthritis. The effects of adalimumab in controlling progression of structural damage in erosive hand osteoarthritis (HOA) were assessed. 
Methods Sixty patients with erosive HOA on radiology received 40 mg adalimumab or placebo subcutaneously every two weeks during a 12-month randomized double-blind trial. Response was defined as the reduction in progression of structural damage according to the categorical anatomic phase scoring system. Furthermore, subchondral bone, bone plate erosion, and joint-space narrowing were scored according to the continuous Ghent University Score System (GUSS (TM)). 
Results The disease appeared to be active since 40.0\% and 26,7\% of patients out of the placebo and adalimumab group, respectively, showed at least one new interphalangeal (IP) joint that became erosive during the 12 months follow-up. These differences were not significant and the overall results showed no effect of adalimumab. Risk factors for progression were then identified and the presence of palpable soft tissue swelling at baseline was recognized as the strongest predictor for erosive progression. In this subpopulation at risk, statistically significant less erosive evolution on the radiological image (3.7\%) was seen in the adalimumab treated group compared to the placebo group (14.5\%) (P = 0.009). GUSSTM scoring confirmed a less rapid rate of mean increase in the erosion scores during the first 6 months of treatment in patients in adalimumab-treated patients. 
Conclusion Palpable soft tissue swelling in IP joints in patients with erosive HOA is a strong predictor for erosive progression. In these joints adalimumab significantly halted the progression of joint damage compared to placebo.},
  author       = {Verbruggen, August and WITTOEK, RUTH and VANDER CRUYSSEN, BERT and Elewaut, Dirk},
  issn         = {0003-4967},
  journal      = {ANNALS OF THE RHEUMATIC DISEASES},
  keyword      = {KAPPA-B LIGAND,RHEUMATOID-ARTHRITIS,SYMPTOMATIC HAND OSTEOARTHRITIS,FACTOR-ALPHA,RADIOGRAPHIC OSTEOARTHRITIS,GENERAL-POPULATION,RECEPTOR ACTIVATOR,PREVALENCE,PROGRESSION,DISABILITY},
  language     = {eng},
  number       = {6},
  pages        = {891--898},
  title        = {Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification},
  url          = {http://dx.doi.org/10.1136/ard.2011.149849},
  volume       = {71},
  year         = {2012},
}

Chicago
Verbruggen, August, RUTH WITTOEK, BERT VANDER CRUYSSEN, and Dirk Elewaut. 2012. “Tumour Necrosis Factor Blockade for the Treatment of Erosive Osteoarthritis of the Interphalangeal Finger Joints: a Double Blind, Randomised Trial on Structure Modification.” Annals of the Rheumatic Diseases 71 (6): 891–898.
APA
Verbruggen, August, WITTOEK, R., VANDER CRUYSSEN, B., & Elewaut, D. (2012). Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification. ANNALS OF THE RHEUMATIC DISEASES, 71(6), 891–898.
Vancouver
1.
Verbruggen A, WITTOEK R, VANDER CRUYSSEN B, Elewaut D. Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification. ANNALS OF THE RHEUMATIC DISEASES. 2012;71(6):891–8.
MLA
Verbruggen, August, RUTH WITTOEK, BERT VANDER CRUYSSEN, et al. “Tumour Necrosis Factor Blockade for the Treatment of Erosive Osteoarthritis of the Interphalangeal Finger Joints: a Double Blind, Randomised Trial on Structure Modification.” ANNALS OF THE RHEUMATIC DISEASES 71.6 (2012): 891–898. Print.